2015
Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection
Walensky RP, Jacobsen MM, Bekker LG, Parker RA, Wood R, Resch SC, Horstman NK, Freedberg KA, Paltiel AD. Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. The Journal Of Infectious Diseases 2015, 213: 1523-1531. PMID: 26681778, PMCID: PMC4837902, DOI: 10.1093/infdis/jiv523.Peer-Reviewed Original ResearchConceptsStandard prepSouth African womenPreexposure prophylaxisHIV infectionHigh riskHuman immunodeficiency virus (HIV) infectionEffective prevention optionsAfrican womenImmunodeficiency virus infectionCost-saving interventionHIV infection riskYoung South African womenLikely clinical benefitInjectable PrEPPrEP formulationsEligible womenClinical benefitPotential ClinicalVirus infectionOutcome measuresPrEP strategiesProgram costsPrevention optionsSurvival rateGreater adherence
2012
The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women
Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, Losina E, Mayer KH, Seage GR, Paltiel AD. The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women. Clinical Infectious Diseases 2012, 54: 1504-1513. PMID: 22474224, PMCID: PMC3334365, DOI: 10.1093/cid/cis225.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisSouth African womenHIV infectionRecent trialsHIV riskLife expectancyHuman immunodeficiency virus (HIV) infectionAfrican womenIncremental cost-effectiveness ratioImmunodeficiency virus infectionAge-adjusted incidenceShort-term efficacyHIV infection incidenceHIV natural historyCost-effectiveness ratioPopulation-level transmissionPrEP efficacyHIV acquisitionLong-term impactPatient outcomesPopulation demographic characteristicsVirus infectionClinical cohortInfection incidenceCost savings
2009
Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy
Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, Weinstein MC, Hicks PL, Aaronson WH, Moore RD, Paltiel AD, Freedberg KA. Racial and Sex Disparities in Life Expectancy Losses among HIV-Infected Persons in the United States: Impact of Risk Behavior, Late Initiation, and Early Discontinuation of Antiretroviral Therapy. Clinical Infectious Diseases 2009, 49: 1570-1578. PMID: 19845472, PMCID: PMC2783631, DOI: 10.1086/644772.Peer-Reviewed Original ResearchConceptsEarly discontinuationHIV infectionAntiretroviral therapyYears of lifeLate initiationRisk behaviorsLate presentationHuman immunodeficiency virus (HIV) infectionHIV Research NetworkLate treatment initiationCohort of HIVImmunodeficiency virus infectionLife expectancyStandardized mortality ratioGeneral US populationHigh-risk profileYears of ageHigh-risk behaviorsSimilar demographic characteristicsRace/ethnicityART discontinuationART initiationCare concordantHispanic HIVAdvanced disease
2005
Expanded Screening for HIV in the United States — An Analysis of Cost-Effectiveness
Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, Losina E, Zhang H, Freedberg KA, Walensky RP. Expanded Screening for HIV in the United States — An Analysis of Cost-Effectiveness. New England Journal Of Medicine 2005, 352: 586-595. PMID: 15703423, DOI: 10.1056/nejmsa042088.Peer-Reviewed Original ResearchConceptsOne-time screeningEnzyme-linked immunosorbent assayGeneral populationHuman immunodeficiency virus (HIV) infectionRoutine HIV counselingEffective antiretroviral therapyImmunodeficiency virus infectionLow-risk populationHigh-risk populationQuality-adjusted survivalCost-effectiveness ratioU.S. general populationAverage survival timeCDC thresholdAntiretroviral therapyHIV screeningHIV antibodiesObservational cohortHIV counselingClinical trialsCost-effectiveness groundsVirus infectionEarly diagnosisVoluntary screeningSurvival time
2003
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection
Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. The American Journal Of Medicine 2003, 115: 632-641. PMID: 14656616, DOI: 10.1016/j.amjmed.2003.07.007.Peer-Reviewed Original ResearchConceptsQuality-adjusted life expectancyHuman immunodeficiency virus (HIV) infectionClinical trial cohortImmunodeficiency virus infectionAdvanced diseaseCost-effectiveness ratioAdherence interventionsAntiretroviral therapyTrial cohortEarly diseaseVirus infectionUrban cohortLife expectancyHIV ribonucleic acid levelsEffective adherence interventionsCD4 cell countCombination antiretroviral therapyVirologic failure ratesLow baseline levelsFailure rateRibonucleic acid levelsStandard careHIV infectionHealthy patientsClinical trials
2001
The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Freedberg K, Losina E, Weinstein M, Paltiel A, Cohen C, Seage G, Craven D, Zhang H, Kimmel A, Goldie S. The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease. New England Journal Of Medicine 2001, 344: 824-831. PMID: 11248160, DOI: 10.1056/nejm200103153441108.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountComputer SimulationCost-Benefit AnalysisDirect Service CostsDisease ProgressionDrug CostsDrug Therapy, CombinationHealth Care CostsHIV InfectionsHumansLife ExpectancyModels, BiologicalQuality-Adjusted Life YearsRNA, ViralUnited StatesValue of LifeConceptsQuality-adjusted yearThree-drug therapyCombination antiretroviral therapyCD4 cell countQuality of lifeAntiretroviral therapyHIV diseaseClinical benefitDrug costsLife expectancyCell countInitial CD4 cell countThree-drug antiretroviral regimensHuman immunodeficiency virus (HIV) infectionHIV RNA levelsPerson lifetime costsImmunodeficiency virus infectionMajor clinical trialsDirect medical costsStandard of careProgression of diseaseLifetime direct medical costsCost-effectiveness ratioServices Utilization SurveyCost effectiveness